N/A
Completed N=3,366
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
Vaccines, Pneumococcal Conjugate Vaccine
Source: ClinicalTrials.gov NCT00683410 ↗
Enrolled (actual)
3,366
Serious AEs
0.1%
Results posted
Nov 2010
Primary outcomePrimary: Number of Participants With Spontaneous Adverse Events — 91 Participants
Summary
To collect post-marketing information on the safety of Prevenar in Filipino patients
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Spontaneous Adverse Events |
91 | — |
Eligibility Criteria
Inclusion Criteria
- All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication.
Exclusion Criteria
- Previously discontinued Prevenar therapy due to safety concerns.
Data sourced from ClinicalTrials.gov (NCT00683410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.